295 related articles for article (PubMed ID: 15586316)
21. Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia.
Popovic V; Doknic M; Maric N; Pekic S; Damjanovic A; Miljic D; Popovic S; Miljic N; Djurovic M; Jasovic-Gasic M; Dieguez C; Casanueva FF
Neuroendocrinology; 2007; 85(4):249-56. PubMed ID: 17570902
[TBL] [Abstract][Full Text] [Related]
22. Sibutramine in the treatment of antipsychotic-induced weight gain: a pilot study in patients with schizophrenia.
Biedermann F; Fleischhacker WW; Kemmler G; Ebenbichler CF; Lechleitner M; Hofer A
Int Clin Psychopharmacol; 2014 May; 29(3):181-4. PubMed ID: 24300751
[TBL] [Abstract][Full Text] [Related]
23. Obesity in schizophrenia: what can be done about it?
Catapano L; Castle D
Australas Psychiatry; 2004 Mar; 12(1):23-5. PubMed ID: 15715734
[TBL] [Abstract][Full Text] [Related]
24. Behavioral therapy for weight loss in patients with schizophrenia.
Ganguli R
J Clin Psychiatry; 2007; 68 Suppl 4():19-25. PubMed ID: 17539696
[TBL] [Abstract][Full Text] [Related]
25. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.
Baptista T; Uzcátegui E; Rangel N; El Fakih Y; Galeazzi T; Beaulieu S; de Baptista EA
Psychiatry Res; 2008 May; 159(1-2):250-3. PubMed ID: 18374423
[TBL] [Abstract][Full Text] [Related]
26. Weight loss in overweight patients maintained on atypical antipsychotic agents.
Centorrino F; Wurtman JJ; Duca KA; Fellman VH; Fogarty KV; Berry JM; Guay DM; Romeling M; Kidwell J; Cincotta SL; Baldessarini RJ
Int J Obes (Lond); 2006 Jun; 30(6):1011-6. PubMed ID: 16432547
[TBL] [Abstract][Full Text] [Related]
27. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?
Le Hellard S; Theisen FM; Haberhausen M; Raeder MB; Fernø J; Gebhardt S; Hinney A; Remschmidt H; Krieg JC; Mehler-Wex C; Nöthen MM; Hebebrand J; Steen VM
Mol Psychiatry; 2009 Mar; 14(3):308-17. PubMed ID: 18195716
[TBL] [Abstract][Full Text] [Related]
28. [Exercising caution in choice of psychotropic drugs. Avoid drug-induced weight gain].
MMW Fortschr Med; 2002 May; Suppl 2():89. PubMed ID: 12070872
[No Abstract] [Full Text] [Related]
29. Psychiatric medication-induced obesity: treatment options.
Schwartz TL; Nihalani N; Virk S; Jindal S; Chilton M
Obes Rev; 2004 Nov; 5(4):233-8. PubMed ID: 15458397
[TBL] [Abstract][Full Text] [Related]
30. Interventions to reduce weight gain in schizophrenia.
Faulkner G; Cohn T; Remington G
Schizophr Bull; 2007 May; 33(3):654-6. PubMed ID: 17449900
[No Abstract] [Full Text] [Related]
31. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
Stahl SM; Mignon L; Meyer JM
Acta Psychiatr Scand; 2009 Mar; 119(3):171-9. PubMed ID: 19178394
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain.
Ellinger LK; Ipema HJ; Stachnik JM
Ann Pharmacother; 2010 Apr; 44(4):668-79. PubMed ID: 20233913
[TBL] [Abstract][Full Text] [Related]
33. Strategies for dosing and switching antipsychotics for optimal clinical management.
Buckley PF; Correll CU
J Clin Psychiatry; 2008; 69 Suppl 1():4-17. PubMed ID: 18484804
[TBL] [Abstract][Full Text] [Related]
34. [Therapeutic options for weight management in schizophrenic patients treated with atypical antipsychotics].
Cordes J; Sinha-Röder A; Kahl KG; Malevani J; Thuenker J; Lange-Asschenfeldt C; Hauner H; Agelink MW; Klimke A
Fortschr Neurol Psychiatr; 2008 Dec; 76(12):703-14. PubMed ID: 18924059
[TBL] [Abstract][Full Text] [Related]
35. Schizophrenia and weight management: a systematic review of interventions to control weight.
Faulkner G; Soundy AA; Lloyd K
Acta Psychiatr Scand; 2003 Nov; 108(5):324-32. PubMed ID: 14531752
[TBL] [Abstract][Full Text] [Related]
36. The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia.
Müller DJ; Klempan TA; De Luca V; Sicard T; Volavka J; Czobor P; Sheitman BB; Lindenmayer JP; Citrome L; McEvoy JP; Lieberman JA; Honer WG; Kennedy JL
Neurosci Lett; 2005 May; 379(2):81-9. PubMed ID: 15823421
[TBL] [Abstract][Full Text] [Related]
37. Prospects for the treatment of obesity.
Proietto J
Med J Aust; 1992 Sep; 157(6):363-4. PubMed ID: 1307233
[No Abstract] [Full Text] [Related]
38. Weight gain in bipolar disorder: pharmacological treatment as a contributing factor.
Torrent C; Amann B; Sánchez-Moreno J; Colom F; Reinares M; Comes M; Rosa AR; Scott J; Vieta E
Acta Psychiatr Scand; 2008 Jul; 118(1):4-18. PubMed ID: 18498432
[TBL] [Abstract][Full Text] [Related]
39. [Challenges in nutrition-based treatment for weight control in adolescents suffering from schizophrenia].
Shani M; Levi M; Zalsman G
Harefuah; 2008 Nov; 147(11):901-5, 939. PubMed ID: 19264012
[TBL] [Abstract][Full Text] [Related]
40. Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia.
Weiden PJ
J Clin Psychiatry; 2007; 68 Suppl 4():34-9. PubMed ID: 17539698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
